CP2

CP2 is a synthetic tricyclic pyrone (pyranopyrone) small molecule originally developed as part of a structure-activity exploration of anti-amyloidogenic agents in the laboratory of Duy H. Hua at Kansas State University and first reported in the biomedical literature as a cell-permeable inhibitor of amyloid-beta oligomeric complex formation in the MC65 neuroblastoma conditional expression system by Maezawa et al. (2006) [1]. The compound consists of a fused tricyclic pyranopyrone skeleton bearing an adenine moiety attached through its N3' nitrogen to the C7 isopropyl substituent of the cyclohexane ring. CP2 exists as two diastereomers, designated D1 and D2, with distinct pharmacological activity and toxicity profiles that have been resolved by X-ray crystallography and cryo-electron microscopy at 3.25 to 3.27 angstrom resolution [2]. The D1 diastereomer is the more pharmacologically active form. The compound was initially characterized as a direct binder of amyloid-beta peptides, with exceptionally high binding affinity to amyloid-beta 40 (Kd approximately 5.05 nanomolar) and high affinity to amyloid-beta 42 (Kd approximately 269 nanomolar), and as an inhibitor of amyloid-beta oligomerization and fibril formation in surface plasmon resonance and atomic force microscopy assays [3, 4]. Subsequent mechanistic investigation by Zhang et al. (2015) identified the primary intracellular target as mitochondrial complex I (NADH:ubiquinone oxidoreductase), the first and largest enzyme complex of the electron transport chain [5]. Molecular dynamics simulations and cryo-electron microscopy demonstrated that the cationic CP2 molecule competes with flavin mononucleotide for binding to the redox subunit of human mitochondrial complex I, leading to mild (partial) inhibition of complex I activity, elevated AMP-to-ATP ratio, and consequent activation of AMP-activated protein kinase (AMPK) in neurons and in mouse brain without inducing oxidative damage or inflammation [5, 6]. In vivo, CP2 is orally bioavailable, penetrates the blood-brain barrier, and accumulates in neuronal mitochondria. Chronic oral administration at 25 mg/kg in drinking water in multiple transgenic mouse models of familial Alzheimer's disease (Tg2576, 3xTg-AD, APP/PS1, 5xFAD) has produced consistent reductions in amyloid-beta and phosphorylated tau accumulation, oxidative stress, neuroinflammation, and cognitive dysfunction, while improving mitochondrial function, energy homeostasis, synaptic activity, dendritic spine density and morphology, and long-term potentiation in the hippocampus [5, 7, 8, 9]. The compound also prevents aggregation and reverses cellular phenotypes caused by expression of mutant huntingtin protein in striatal neurons, extending the potential disease relevance beyond Alzheimer's disease to Huntington's disease [10]. A 2025 study by Gao et al. demonstrated that mitochondrial complex I deficiency alone induces Alzheimer's disease-like transcriptomic signatures in the brain, and that these signatures are partially reversible by CP2 treatment, providing further mechanistic support for the therapeutic strategy [11]. CP2 has not entered human clinical trials. The compound remains a preclinical research tool and investigational candidate. Structure-activity relationship studies have produced a next-generation analog, C458 (cis-(N-(pyridin-4-ylmethyl)-2-(3-(m-tolyloxy)cyclohexyl)propan-1-amine)), with improved drug-like properties, favorable pharmacokinetics, minimal off-target effects, and excellent brain penetrance [2, 12]. This monograph reviews the chemistry, synthesis, and stereochemistry of CP2; the dual mechanism of action encompassing direct amyloid-beta binding and mild mitochondrial complex I inhibition; the pharmacokinetic profile in rodents; the preclinical evidence base across Alzheimer's disease and Huntington's disease models; sourcing and handling considerations for laboratory use; stack interaction considerations; the adverse event and safety signal from preclinical data; and a comparative assessment of five mitochondrial-targeted or anti-amyloidogenic neuroprotective candidates against CP2 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation). The compound is not approved by any regulatory agency and is not registered as a medicine in any jurisdiction. It is supplied as a research-grade preparation; investigators should obtain analytical confirmation of identity and purity on every lot.